Efficacy of pregabalin in the management of cetuximab-related itch.
Porzio
Giampiero
G
Aielli
Federica
F
Verna
Lucilla
L
Porto
Claudio
C
Tudini
Marianna
M
Cannita
Katia
K
Ficorella
Corrado
C
D000700:Analgesics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000068818:Cetuximab; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069583:Pregabalin; D011537:Pruritus / Q000139:chemically induced* / Q000188:drug therapy*; D016896:Treatment Outcome; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000700:Analgesics; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000068818:Cetuximab